111 Capital Makes New Investment in Boston Scientific Corporation $BSX

111 Capital purchased a new stake in shares of Boston Scientific Corporation (NYSE:BSX) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 30,717 shares of the medical equipment provider’s stock, valued at approximately $2,999,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Steph & Co. purchased a new position in Boston Scientific in the third quarter valued at about $25,000. Financial Consulate Inc. bought a new stake in shares of Boston Scientific in the 3rd quarter valued at approximately $25,000. Murphy & Mullick Capital Management Corp increased its holdings in Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 170 shares during the last quarter. FWL Investment Management LLC bought a new position in Boston Scientific during the second quarter valued at approximately $26,000. Finally, United Community Bank lifted its stake in Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 147 shares during the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Street sentiment and recent analyst commentary lean favorable after the company’s quarterly results and guidance; the board added Cathy Smith and Christophe Weber, which investors view as governance/strategic strengthening. What Does the Street Think About Boston Scientific Corporation (BSX)?
• Positive Sentiment: Boston Scientific arranged multiple credit facilities totaling roughly $11 billion, boosting liquidity and providing financial flexibility for M&A, R&D, or share-repurchase plans — a constructive sign for risk management and capital strategy. Boston Scientific enters into multiple credit facilities totaling $11B
• Positive Sentiment: Management promoted an internal candidate to president of Vascular Therapies, signaling leadership continuity and succession depth in a key growth division. Boston Scientific promotes new president of Vascular Therapies from within
• Neutral Sentiment: Market coverage notes BSX is “trending” and trading up relative to the broader market on the session, driven partly by investor interest after earnings — useful for short-term flows but not a fundamental change. Boston Scientific (BSX) Ascends While Market Falls: Some Facts to Note
• Neutral Sentiment: Commentary points out BSX has trailed the Dow over recent periods despite analyst optimism — flags for investors focused on relative performance and timing for rotation into healthcare. Is Boston Scientific Stock Underperforming the Dow?
• Negative Sentiment: FDA-linked reporting: Boston Scientific halted use of certain AXIOS stent delivery devices after deployment issues associated with 167 injuries and three deaths — a material product-safety concern that can affect revenue, litigation exposure and reputation in the short-to-medium term. Boston Scientific Halts Use Of Select Stent Delivery Devices After Patient Deaths
• Negative Sentiment: An investor law firm (Pomerantz) has opened an investigation into claims on behalf of BSX investors, increasing legal risk and potential headline volatility. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation – BSX

Boston Scientific Price Performance

NYSE BSX opened at $76.68 on Monday. The stock has a 50-day simple moving average of $87.31 and a 200 day simple moving average of $95.55. Boston Scientific Corporation has a twelve month low of $72.69 and a twelve month high of $109.50. The stock has a market capitalization of $113.78 billion, a PE ratio of 39.52, a P/E/G ratio of 1.06 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The company had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. During the same period in the previous year, the business posted $0.70 EPS. The company’s revenue for the quarter was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on BSX. TD Cowen dropped their price target on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, February 2nd. Citigroup lowered their target price on shares of Boston Scientific from $130.00 to $102.00 and set a “buy” rating on the stock in a research report on Thursday, February 5th. Evercore cut their target price on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. JPMorgan Chase & Co. decreased their price target on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Finally, Needham & Company LLC lowered their price objective on Boston Scientific from $121.00 to $97.00 and set a “buy” rating on the stock in a report on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $108.36.

Insider Transactions at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.50% of the stock is owned by corporate insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.